NovartisNVS.NValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 16, 2026, Novartis (NVS.N) trades at a P/E of 22.40x, P/B of 6.90x, P/S of 5.05x, and a dividend yield of 2.06%.
Longitudinal percentile comparison: P/E sits at the 63rd percentile over the trailing 10Y window (vs. 86th percentile over 3Y); P/B sits at the 96th percentile over the trailing 10Y window (vs. 88th percentile over 3Y); P/S sits at the 96th percentile over the trailing 10Y window (vs. 85th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 46th percentile within its industry and the 58th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 5.28%, ranking at the 48th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 33.4 points apart — worth checking the full percentile matrix on this page for the complete picture. The P/E percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Of the 5.28% total shareholder yield, 2.06% is paid out as dividends and roughly 3.22% is implied to come from buybacks — both channels are meaningfully in play. Novartis operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NYSE: NVS · NVS
Want the full picture on whether Novartis (NVS.N) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 22.40 | ||||||
| P/B (MRQ) | 6.90 | ||||||
| P/S (TTM) | 5.05 | ||||||
| Dividend Yield | 2.06% | ||||||
| Buyback + Div Yield | 5.28% |